AMGN · 10-Q · 2026Q3

AMGEN INC

Filed 2026-11-04 · Healthcare · View original filing on EDGAR

Ranked Events

• Capital Expenditures ProgramImportance 93 · Surprise 82
  Capital expenditures were $1.8 billion during the nine months ended September 30, 2026, compared with $1.2 billion in the same 2025 period. The spending primarily funded construction of new plants and…
• Prolia Biosimilar CompetitionImportance 84 · Surprise 74
  Prolia sales fell 45% globally in the third quarter and 37% in the first nine months of 2026 as multiple biosimilars launched in the U.S. and ROW. Nine-month sales declined to $2.118 billion from $3.360 billion. The…
• XGEVA Biosimilar CompetitionImportance 78 · Surprise 74
  Global XGEVA sales decreased 47% in the third quarter and 36% in the first nine months of 2026 as multiple biosimilars launched in the U.S. and ROW. Nine-month sales fell to $1.051 billion from $1.637 billion. The…
• Repatha Demand GrowthImportance 64 · Surprise 56
  Global Repatha sales increased for the three and nine months ended September 30, 2026, primarily because of volume growth. Nine-month sales rose to $2.914 billion from $2.146 billion, an increase of approximately 36%.…
• Liquidity and Debt PositionImportance 64 · Surprise 56
  At September 30, 2026, cash and cash equivalents were $13.190 billion, up from $9.129 billion at December 31, 2025; total assets were $96.048 billion. Current and long-term debt were $2.398 billion and $51.609 billion,…
• Operating Expense TrendsImportance 60 · Surprise 40
  Research and development expense increased 11% to $2.111 billion for the three months ended September 30, 2026, and increased 11% to $5.698 billion for the nine months. Quarterly R&D growth reflected higher Research…
• Operating Cash Flow TrendsImportance 59 · Surprise 48
  Net cash provided by operating activities increased to $10.432 billion for the nine months ended September 30, 2026, from $8.355 billion in the prior-year period. The increase primarily reflected the final $1.8 billion…
• Medicare Drug Price SettingImportance 58 · Surprise 42
  In January 2025, the Centers for Medicare & Medicaid Services selected Otezla for Medicare price setting, applicable beginning January 1, 2027. Amgen says the earlier-than-anticipated selection reduced estimated future…
• Enbrel Pricing PressureImportance 56 · Surprise 58
  Enbrel’s nine-month sales declined 11% to $1.511 billion, primarily reflecting a 19% lower net selling price. Amgen attributed the lower price to the ongoing impact of U.S. Medicare Part D price setting effective in…
• Otezla Generic CompetitionImportance 56 · Surprise 58
  Global Otezla sales declined 18% in the third quarter and 14% in the first nine months of 2026; nine-month sales were $1.403 billion versus $1.640 billion. ROW sales were adversely affected by generic competition after…
• IRS Tax DisputesImportance 50 · Surprise 24
  The IRS disputes the allocation of profits between Amgen entities in the United States and Puerto Rico for tax years 2010–2015, seeking approximately $3.6 billion and $5.1 billion in additional federal tax,…
• Operating Income and MarginsImportance 49 · Surprise 32
  Operating expenses were $6.655 billion for the third quarter of 2026, down 5% year over year, and $19.147 billion for the first nine months, down 7%. The company attributed the decreases to lower amortization expense…
• Revenue Performance and MixImportance 49 · Surprise 32
  Worldwide product sales for the three months ended September 30, 2026 rose 8% to $9.883 billion from $9.137 billion, and nine-month sales rose 7% to $27.638 billion from $25.781 billion. Repatha sales increased on…
• IRS Tax ExaminationsImportance 47 · Surprise 60
  The IRS is examining Amgen’s 2016–2018 tax years and issued draft proposed adjustments in April 2026, reissued in May and July, concerning allocation of profits between U.S. entities and the U.S. territory of Puerto…
• Tavneos FDA Withdrawal ProposalImportance 47 · Surprise 60
  On April 27, 2026, FDA’s Center for Drug Evaluation and Research (CDER) proposed withdrawing TAVNEOS’s U.S. approval, citing alleged lack of substantial evidence of effectiveness and untrue material statements in the…
• U.S. Tax Law ChangesImportance 47 · Surprise 60
  The United States enacted the One Big Beautiful Bill Act (OB3) on July 4, 2025, with most provisions effective January 1, 2026. The law modifies the international tax framework, and Amgen says its foreign earnings are…
• Gross Margin DriversImportance 46 · Surprise 40
  Cost of sales fell 10% to $2.788 billion for the third quarter and 8% to $8.343 billion for the first nine months of 2026. Cost of sales decreased to 26.9% of total revenues for the quarter and 28.7% for the nine-month…
• Capital Return ProgramImportance 43 · Surprise 32
  Amgen paid $4.1 billion of dividends during the nine months ended September 30, 2026, compared with $3.8 billion in the prior-year period. The Board declared quarterly dividends of $2.52 per share for each of the first…
• Trade Policy and TariffsImportance 40 · Surprise 42
  Amgen reports that the U.S. Administration issued a proclamation in April 2026 imposing Section 232 tariffs on certain patented pharmaceuticals and associated active pharmaceutical ingredients. The company says it…
• Drug Pricing Policy ImpactImportance 40 · Surprise 42
  Amgen states that the Inflation Reduction Act (IRA) and expanded use of 340B discounts have negatively affected, and are likely to continue to negatively affect, its business. CMS selected ENBREL for Medicare price…

Revenue by Product (in millions)

Revenue by Geography (in millions)